Skip to Content

Kirk S. Culotta, Pharm.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Scientific Director, Pharmaceutical Development Center, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Research Interests

  • IND-Directed Drug Development
  • Clinical Pharmacology
  • Pharmacokinetics

Education & Training

Degree-Granting Education

2003 Xavier University, New Orleans, LA, PHARMD, Magna Cum Laude, Pharmacy
1995 University of New Orleans, New Orleans, LA, BS, Biological Sciences

Postgraduate Training

2003-2005 Clinical Fellowship, Pharmacology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Timothy Madden


Other Appointments/Responsibilities

Clinical Pharmacy Specialist, CTRC, The University of Texas MD Anderson Cancer Center,Department of Pharmacology Research, Division of Pharmacy, Houston, TX, 2005-2010

Institutional Committee Activities

Member, MD Anderson Cancer Center Clinical Research Committee, 2006-present
Member, MD Anderson Cancer Center Clinical & Translational Research Center Steering Committee, 2006-present

Honors and Awards

2009 Performance Award, Pharmacy Busulfan Pharmacokinetics, UT MD Anderson Cancer Center
2008 Performance Award, Clinical Research, UT MD Anderson Cancer Center
2001 Alpha Kappa Mu Science Honor Society, College of Pharmacy, Xavier University
1994 Beta Beta Beta Biology Honor Society, University of New Orleans
1991-1995 University Honors Program, University of New Orleans

Selected Publications

Peer-Reviewed Original Research Articles

1. Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng CS, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res 18(4):1120-8, 2/15/2012. e-Pub 1/5/2012. PMID: 22223528.
2. Gulbis AM, Culotta KS, Jones RB, Andersson BS. Busulfan and metronidazole: an often forgotten but significant drug interaction. Ann Pharmacother 45(7-8):e39, 7/2011. e-Pub 7/2011. PMID: 21730282.
3. Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R.. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound Paclitaxel: toxicity, pharmacokinetics, and activity. Molecular Cancer Therapeutics 10(7):1300-13007, 7/2011. e-Pub 5/2011. PMID: 21571911.
4. Brooks HD, Glisson BS, Bekele BN, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117(10):2112-9, 5/2011. e-Pub 11/2010. PMID: 21523723.
5. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2(11):931-41, 11/2009. PMID: 19892663.
6. Aviles DH, Vehaskari MV, Culotta KS, Manning J, Ochoa AC, Zea AH. T cell CD3 receptor zeta (TCRzeta)-chain expression in children with idiopathic nephrotic syndrome. Pediatr Nephrol 24(4):769-73, 4/2009. e-Pub 12/2008. PMID: 19082633.
7. Zea AH, Culotta KS, Ali J, Mason C, Park HJ, Zabaleta J, Garcia LF, Ochoa AC. Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J Infect Dis 194(10):1385-93, 11/2006. e-Pub 10/2006. PMID: 17054067.
8. Zea AH, Rodriguez PC, Culotta KS, Hernandez CP, DeSalvo J, Ochoa JB, Park HJ, Zabaleta J, Ochoa AC. L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol 232(1-2):21-31, Nov-Dec, 11/2004. e-Pub 2/2005. PMID: 15922712.
9. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, Ochoa JB, Ochoa AC. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 171(3):1232-9, 8/1/2003. PMID: 12874210.
10. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem 277(24):21123-9, 6/2002. e-Pub 4/2002. PMID: 11950832.
11. Taheri F, Ochoa JB, Faghiri Z, Culotta K, Park H, Lan M, Zea A, Ochoa AC. L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clinical Cancer Research 7(3):958s-965s, 3/2001. PMID: 11300497.


1. Xu Q, Norberg L, Culotta K, Johansen MJ, Madden T. Determination of Free Oxaliplatin in Human Plasma Ulftrafiltrate by LC-MS/MS. Pttcon 2011 (#2160-22), 4/2011.
2. Culotta K, Kurzrock R, Stewart C, Dorsey V, Harleaux-Grant D, Wyles M, Kramer M, Zhang Y, Madden T, Karp D. Emergence of oral targeted agents in early clinical development: experience at MD Anderson Cancer Center – Clinical and Translational Research Center. Proceedings of the 50th ASCO Annual Meeting. (#3073), 6/2010.
3. Brooks HD, Glisson B, Bekele B, Culotta K, Ginsberg L, Johnson F, Lu C, Sabichi A, Tran H, Papadimitrakopoulou V. Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma. Proceedings of the 49th ASCO Annual Meeting. (#6022), 5/2009.
4. Culotta K, Covey J, Schultz C, Hollingshead M, Carter J, Borgel S, Bonomi C, Tomaszweski J, Johansen M, Madden T. Preclinical pharmacokinetic and comparative biodistribution studies of NSC 706744, NSC 724998, and NSC 725776, three novel indenoisoquinoline topoisomerase I poisons, in CD2F1 mice. Proceedings of the 99th AACR Annual Meeting (#785), 4/2008.
5. Culotta K, Kirkpatrick D, Covey J, Schultz C, Mack D, Rhea R, Allen T, Powis G, Johansen M, Madden T. Preclinical pharmacokinetic and comparative biodistribution studies of PX-866, a broad spectrum phospha-tidylinositol-3-kinase (PI-3K) inhibitor, in F344 rats. Proceedings of the 18th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics (#434), 11/2006.

Last updated: 12/10/2013